← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Szela Mary T
Chief Executive Officer | Director | President
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001410289
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 3
- Purchases · 24M
- 5
- Average purchase
- $95.7K
- Median purchase
- $102.8K
- Gross purchase value
- $478.7K
Companies: Absci Corp | TriSalus Life Sciences, Inc.
5 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-06 | Absci Corp | ABSI | Director | $148.9K | Open filing |
| 2026-05-18 | TriSalus Life Sciences, Inc. | TLSI | Chief Executive Officer | President | $102.8K | Open filing |
| 2026-02-23 | TriSalus Life Sciences, Inc. | TLSI | Chief Executive Officer | President | $125.0K | Open filing |
| 2025-01-31 | TriSalus Life Sciences, Inc. | TLSI | Chief Executive Officer | President | $51.8K | Open filing |
| 2025-01-29 | TriSalus Life Sciences, Inc. | TLSI | Chief Executive Officer | President | $50.3K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small Sample | 80.0% (4/5) | 75.0% (3/4) | +6.6% | +5.6% | -0.2% |
| 20D | 4Small Sample | 80.0% (4/5) | 75.0% (3/4) | +16.2% | +12.6% | -17.7% |
| 60D | 4Small Sample | 80.0% (4/5) | 75.0% (3/4) | +22.5% | +20.1% | -44.7% |
| 120D | 3Small Sample | 100.0% (3/3) | 0.0% (0/3) | -9.9% | -12.0% | -17.3% |
Research patterns
- First purchase in 12M
- 2/4
- Large purchase ≥ $100k
- 3/5
- Cluster buying · 15D
- 4/5
- Buying the dip
- 4/4
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.